Ian Lonergan, DO
Plastic and Reconstructive Surgery · Wilmington, DENPI 1174795744
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $364,063 of the $364,388 with a category attached, or 99.9%. CSL Plasma Inc. accounts for 76.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $114,375, more than ten times the $111 reported in 2019.
Across 377 payments — averaging $966.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$280K
- CSL Behring$84K
- Smith+Nephew$78
- AbbVie$52
- Convatec Inc.$40
- Avanos Medical$38
- plus $117 from 6 others
What the payments were for
- Consulting fees$364,063100%
- Food & beverage$3260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 290 | $279,938 |
| CSL Behring | 70 | $84,125 |
| Smith+Nephew | 4 | $78 |
| AbbVie(2 entities) | 3 | $52 |
| Convatec Inc. | 2 | $40 |
| Avanos Medical | 1 | $38 |
| Organogenesis Inc. | 2 | $35 |
| Integra Lifesciences Corporation | 1 | $24 |
| Urgo Medical North America, LLC | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Mimedx Group, Inc. | 1 | $14 |
| Medtronic | 1 | $11 |
How this compares
Too few plastic and reconstructive surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 190 | $736 |
| Doxycycline Hyclate | 13 | $121 |
| Azithromycin | 14 | $101 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Wilmington
- Benjamin CooperWilmington$737
- Rhoda PowellWilmington$17
- John RoussalisNewark$13K
- Amir ArsalanNewark$3K
- Stephanie CatersonNewark$2K
- Jonathan SarikMilford$1K
- Jonathan SaundersNewark$237
- Julia MacraeNewark$226
- Mehdi BalakhaniNewark$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.